Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans

Journal of General Virology

Volumn 97, Issue 8, 2016, Pages 1807-1817

  To, Kelvin K W ^a,b   Mok, Ka Yi ^b   Chan, Andy S F ^b   Cheung, Nam N ^b   Wang, Pui ^b   Lui, Yin Ming ^b   Chan, Jasper F W ^a,b   Chen, Honglin ^a,b,c   Chan, Kwok Hung ^a,b   Kao, Richard Y T ^a,b   Yuen, Kwok Yung ^a,b,c  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Broad spectrum; Guanosine; Host targeted antiviral; Polymerase inhibitor; Respiratory virus

Indexed keywords

ANTIVIRUS AGENT; GUANOSINE; MYCOPHENOLIC ACID; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFLUENZA VIRUS; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG EFFECT; DRUG MECHANISM; IC50; IMMUNOMODULATION; IN VITRO STUDY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H7N9); INFLUENZA B VIRUS; MDCK CELL LINE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SEASONAL INFLUENZA; VIRAL PLAQUE ASSAY; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CELL SURVIVAL; DOG; DRUG EFFECTS; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; DOGS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INHIBITORY CONCENTRATION 50; MADIN DARBY CANINE KIDNEY CELLS; MYCOPHENOLIC ACID; VIRAL LOAD; VIRUS REPLICATION;

EID: 84985905296     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/jgv.0.000512     Document Type: Article

References (73)

1. Allison, A. C. & Eugui, E. M. (2000). Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47, 85–118.
2. Anonymous. Mycophenolic acid. In DRUGDEX® System [Internet database]. Micromedex® 2.0. Accessed on 23 July 2013.
3. Baker, S. F., Nogales, A., Finch, C., Tuffy, K. M., Domm, W., Perez, D. R., Topham, D. J. & Martínez-Sobrido, L. (2014). Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J Virol 88, 10778–10791.
4. Baranovich, T., Wong, S. S., Armstrong, J., Marjuki, H., Webby, R. J., Webster, R. G. & Govorkova, E. A. (2013). T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87, 3741–3751.
5. Beduschi, M. G., Guimarães, C. L., Buss, Z. S. & Dalmarco, E. M. (2013). Mycophenolate mofetil has potent anti-inflammatory actions in a mouse model of acute lung injury. Inflammation 36, 729–737.
6. Belardo, G., Cenciarelli, O., La Frazia, S., Rossignol, J. F. & Santoro, M. G. (2015). Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob Agents Chemother 59, 1061–1069.
7. Blaising, J., Polyak, S. J. & Pècheur, E. I. (2014). Arbidol as a broadspectrum antiviral: an update. Antiviral Res 107, 84–94.
8. Blum, C. A., Nigro, N., Briel, M., Schuetz, P., Ullmer, E., Suter-Widmer, I., Winzeler, B., Bingisser, R., Elsaesser, H. & other authors (2015). Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385, 1511–1518.
9. Burnham, A. J., Baranovich, T. & Govorkova, E. A. (2013). Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 100, 520–534.
10. Cao, R. Y., Xiao, J. H., Cao, B., Li, S., Kumaki, Y. & Zhong, W. (2014). Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antivir Chem Chemother 23, 237–240.
11. Carr, S., Ilyushina, N. A., Franks, J., Adderson, E. E., Caniza, M., Govorkova, E. A. & Webster, R. G. (2011). Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 30, 284–288.
12. Chan, J. F., Chan, K. H., Kao, R. Y., To, K. K., Zheng, B. J., Li, C. P., Li, P. T., Dai, J., Mok, F. K. & other authors (2013a). Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67, 606–616.
13. Chan, K. H., To, K. K., Chan, J. F., Li, C. P., Chen, H. & Yuen, K. Y. (2013b). Analytical sensitivity of seven point-of-care influenza virus detection tests and two molecular tests for detection of avian origin H7N9 and swine origin H3N2 variant influenza A viruses. J Clin Microbiol 51, 3160–3161.
14. Chan, K. H., To, K. K., Hung, I. F., Zhang, A. J., Chan, J. F., Cheng, V. C., Tse, H., Che, X. Y., Chen, H. & other authors (2011). Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin Vaccine Immunol 18, 867–873.
15. Chapuis, A. G., Paolo Rizzardi, G., D’Agostino, C., Attinger, A., Knabenhans, C., Fleury, S., Acha-Orbea, H. & Pantaleo, G. (2000). Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 6, 762–768.
16. Chen, Y., Liang, W., Yang, S., Wu, N., Gao, H., Sheng, J., Yao, H., Wo, J., Fang, Q. & other authors (2013). Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 381, 1916–1925.
17. Cheng, V. C., To, K. K., Tse, H., Hung, I. F. & Yuen, K. Y. (2012). Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev 25, 223–263.
18. Cline, J. C., Nelson, J. D., Gerzon, K., Williams, R. H. & Delong, D. C. (1969). In vitro antiviral activity of mycophenolic acid and its reversal by guanine-type compounds. Appl Microbiol 18, 14–20.
19. ClinicalTrials.gov. Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults. Available at http://www.clinicaltrials.gov/show/NCT02008344. Accessed on 22 August 2014.
20. Daikoku, T., Yoshida, Y., Okuda, T. & Shiraki, K. (2014). Characterization of susceptibility variants of influenza virus grown in the presence of T- 705. J Pharmacol Sci 126, 281–284.
21. Diamond, M. S., Zachariah, M. & Harris, E. (2002). Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304, 211–221.
22. Dobson, J., Whitley, R. J., Pocock, S. & Monto, A. S. (2015). Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 385, 1729–1737.
23. Escuret, V., Collins, P. J., Casalegno, J. S., Vachieri, S. G., Cattle, N., Ferraris, O., Sabatier, M., Frobert, E., Caro, V. & other authors (2014). A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses. J Infect Dis 210, 1260–1269.
24. Fischer, A., Brown, K. K., Du Bois, R. M., Frankel, S. K., Cosgrove, G. P., Fernandez-Perez, E. R., Huie, T. J., Krishnamoorthy, M., Meehan, R. T. & other authors (2013). Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40, 640–646.
25. Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F. & Barnard, D. L. (2013). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100, 446–454.
26. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H. & Shiraki, K. (2005). Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49, 981–986.
27. Garg, S., Moore, Z., Lee, N., McKenna, J., Bishop, A., Fleischauer, A., Springs, C. B., Nguyen, H. T., Sheu, T. G. & other authors (2013). A cluster of patients infected with I221V influenza B virus variants with reduced oseltamivir susceptibility—North Carolina and South Carolina, 2010-2011. J Infect Dis 207, 966–973.
28. Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., Rossignol, J. F. & US Nitazoxanide Influenza Clinical Study Group (2014). Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 14, 609–618.
29. Heneghan, C. J., Onakpoya, I., Thompson, M., Spencer, E. A., Jones, M. & Jefferson, T. (2014). Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348, g2547.
30. Hung, I. F., To, K. K., Lee, C. K., Lee, K. L., Chan, K., Yan, W. W., Liu, R., Watt, C. L., Chan, W. M. & other authors (2011). Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52, 447–456.
31. Hung, I. F., To, K. K., Lee, C. K., Lee, K. L., Yan, W. W., Chan, K., Chan, W. M., Ngai, C. W., Law, K. I. & other authors (2013). Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144, 464–473.
32. Jefferson, T., Jones, M., Doshi, P., Spencer, E. A., Onakpoya, I. & Heneghan, C. J. (2014). Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348, g2545.
33. Kao, R. Y., Yang, D., Lau, L. S., Tsui, W. H., Hu, L., Dai, J., Chan, M. P., Chan, C. M., Wang, P. & other authors (2010). Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28, 600–605.
34. Khan, M., Dhanwani, R., Patro, I. K., Rao, P. V. & Parida, M. M. (2011). Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 89, 1–8.
35. Kiselev, O. I., Maleev, V. V., Deeva, ÉG., Leneva, I. A., Sel’kova, E. P., Osipova, E. A., Obukhov, A. A., Nadorov, S. A. & Kulikova, E. V. (2015). [Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo- controlled study ARBITR]. Ter Arkh 87, 88–96 (in Russian).
36. Lejal, N., Tarus, B., Bouguyon, E., Chenavas, S., Bertho, N., Delmas, B., Ruigrok, R. W., Di Primo, C. & Slama-Schwok, A. (2013). Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother 57, 2231–2242.
37. Li, I. W., Chan, K. H., To, K. W., Wong, S. S., Ho, P. L., Lau, S. K., Woo, P. C., Tsoi, H. W., Chan, J. F. & other authors (2009). Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. J Clin Virol 46, 325–330.
38. Luke, T. C., Kilbane, E. M., Jackson, J. L. & Hoffman, S. L. (2006). Metaanalysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145, 599–609.
39. Mok, B. W., Song, W., Wang, P., Tai, H., Chen, Y., Zheng, M., Wen, X., Lau, S. Y., Wu, W. L. & other authors (2012). The NS1 protein of influenza A virus interacts with cellular processing bodies and stress granules through RNA-associated protein 55 (RAP55) during virus infection. J Virol 86, 12695–12707.
40. Morgenstern, B., Michaelis, M., Baer, P. C., Doerr, H. W. & Cinatl, J. (2005). Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 326, 905–908.
41. Muthuri, S. G., Venkatesan, S., Myles, P. R., Leonardi-Bee, J., Al Khuwaitir, T. S., Al Mamun, A., Anovadiya, A. P., Azziz- Baumgartner, E., Bàez, C. & other authors (2014). Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2, 395–404.
42. Ölschläger, S., Neyts, J. & Günther, S. (2011). Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res 91, 89–93.
43. Pan, M., Gao, R., Lv, Q., Huang, S., Zhou, Z., Yang, L., Li, X., Zhao, X., Zou, X. & other authors (2016). Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: Virological and clinical findings. J Infect 72, 52–59.
44. Priore, S. F., Moss, W. N. & Turner, D. H. (2012). Influenza A virus coding regions exhibit host-specific global ordered RNA structure. PLoS One 7, e35989.
45. Priore, S. F., Moss, W. N. & Turner, D. H. (2013). Influenza B virus has global ordered RNA structure in (+) and (-) strands but relatively less stable predicted RNA folding free energy than allowed by the encoded protein sequence. BMC Res Notes 6 330.
46. Qiu, L. W., Liao, Z. Y., Wang, Y. D., Ding, X. X., Di, B., Yuen, K. Y. & Che, X. Y. (2009). Development and application of monoclonal antibodies- based antigen capture ELISA for detecting nucleocapsid protein of Influenza B virus. Guangdong Medecal Journal 30, 1435–1438.
47. Sebastian, L., Madhusudana, S. N., Ravi, V. & Desai, A. (2011). Mycophenolic acid inhibits replication of Japanese encephalitis virus. Chemotherapy 57, 56–61.
48. Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I. & other authors (2008). Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52, 3284–3292.
49. Smee, D. F., Tarbet, E. B., Furuta, Y., Morrey, J. D. & Barnard, D. L. (2013). Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol 8, 1085–1094.
50. Su, S., Chaves, S. S., Perez, A., D’Mello, T., Kirley, P. D., Yousey- Hindes, K., Farley, M. M., Harris, M., Sharangpani, R. & other authors (2014). Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin Infect Dis 59, 252–255.
51. Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., Fry, A., Gregory, V., Leang, S. K. & other authors (2015). Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res 117, 27–38.
52. To, K. K., Hung, I. F., Li, I. W., Lee, K. L., Koo, C. K., Yan, W. W., Liu, R., Ho, K. Y., Chu, K. H. & other authors (2010). Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 50, 850–859.
53. To, K. K., Ng, K. H., Que, T. L., Chan, J. M., Tsang, K. Y., Tsang, A. K., Chen, H. & Yuen, K. Y. (2012). Avian influenza A H5N1 virus: a continuous threat to humans. Emerg Microbes Infect 1, e25.
54. To, K. K., Chan, J. F., Chen, H., Li, L. & Yuen, K. Y. (2013). The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis 13, 809–821.
55. To, K. K., Chan, J. F. & Yuen, K. Y. (2014a). Viral lung infections: epidemiology, virology, clinical features, and management of avian influenza A (H7N9). Curr Opin Pulm Med 20, 225–232.
56. To, K. K., Tsang, A. K., Chan, J. F., Cheng, V. C., Chen, H. & Yuen, K. Y. (2014b). Emergence in China of human disease due to avian influenza A (H10N8)-cause for concern? J Infect 68, 205–215.
57. To, K. K., Zhang, A. J., Chan, A. S., Li, C., Cai, J. P., Lau, C. C., Li, C. G., Jahan, A. S., Wu, W. L. & other authors (2015). Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection. Arch Virol 160, 777–786.
58. Torres, A., Sibila, O., Ferrer, M., Polverino, E., Menendez, R., Mensa, J., Gabarrús, A., Sellarès, J., Restrepo, M. I. & other authors (2015). Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313, 677–686.
59. Van Gelder, T. & Hesselink, D. A. (2015). Mycophenolate revisited. Transpl Int 28, 508–515.
60. Vethe, N. T., Bremer, S., Rootwelt, H. & Bergan, S. (2008). Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther Drug Monit 30, 647–655.
61. Villarroel, M. C., Hidalgo, M. & Jimeno, A. (2009). Mycophenolate mofetil: An update. Drugs of Today 45, 521–532.
62. Wakai, C., Iwama, M., Mizumoto, K. & Nagata, K. (2011). Recognition of cap structure by influenza B virus RNA polymerase is less dependent on the methyl residue than recognition by influenza A virus polymerase. J Virol 85, 7504–7512.
63. Wang, C. H., Chung, F. T., Lin, S. M., Huang, S. Y., Chou, C. L., Lee, K. Y., Lin, T. Y. & Kuo, H. P. (2014a). Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med 42, 313–321.
64. Wang, Y., Zhou, X., Debing, Y., Chen, K., Van Der Laan, L. J., Neyts, J., Janssen, H. L., Metselaar, H. J., Peppelenbosch, M. P. & other authors (2014b). Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 146, 1775–1783.
65. Watanabe, T., Kawakami, E., Shoemaker, J. E., Lopes, T. J., Matsuoka, Y., Tomita, Y., Kozuka-Hata, H., Gorai, T., Kuwahara, T. & other authors (2014). Influenza virus-host interactome screen as a platform for antiviral drug development. Cell Host Microbe 16, 795–805.
66. Watanabe, T. & Kawaoka, Y. (2015). Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol 14, 71–78.
67. Wunderlich, K., Juozapaitis, M., Mänz, B., Mayer, D., Götz, V., Zöhner, A., Wolff, T., Schwemmle, M. & Martin, A. (2010). Limited compatibility of polymerase subunit interactions in influenza A and B viruses. J Biol Chem 285, 16704–16712.
68. Yang, Y. F., Tan, D. M., Xie, Y. T., Zhao, W., Hou, Z. H. & Zhong, Y. D. (2008). Mycophenolate mofetil prevents lethal acute liver failure in mice induced by bacille Calmette-Guèrin and lipopolysaccharide. J Gastroenterol Hepatol 23, 611–618.
69. Ye, L., Li, J., Zhang, T., Wang, X., Wang, Y., Zhou, Y., Liu, J., Parekh, H. K. & Ho, W. (2012). Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells. Virus Res 168, 33–40.
70. Yu, L., Wang, Z., Chen, Y., Ding, W., Jia, H., Chan, J. F., To, K. K., Chen, H., Yang, Y. & other authors (2013). Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis 57, 1449–1457.
71. Yuen, K. Y., Chan, P. K., Peiris, M., Tsang, D. N., Que, T. L., Shortridge, K. F., Cheung, P. T., To, W. K., Ho, E. T. & other authors (1998). Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351, 467–471.
72. Zheng, B. J., Chan, K. W., Lin, Y. P., Zhao, G. Y., Chan, C., Zhang, H. J., Chen, H. L., Wong, S. S., Lau, S. K. & other authors (2008). Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 105, 8091–8096.
73. Zumla, A., Memish, Z. A., Maeurer, M., Bates, M., Mwaba, P., Al- Tawfiq, J. A., Denning, D. W., Hayden, F. G. & Hui, D. S. (2014). Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis 14, 1136–1149.